Artificial Intelligence Technology Solutions, Inc.: AITX's PURSUON Reports Growing ROAMEO Deployment Pipeline and Expands Production Readiness in Support of Its Stated Goal of 50 Units by August 2027

Artificial Intelligence Technology Solutions Inc. (AITX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Artificial Intelligence Technology Solutions, Inc.: Exhibit 99.1 - Filed by newsfilecorp.com Exhibit 99.1 AITX Reports Q1 FY2027 Results: Total Revenue of $1.83 Million; Revenue Excluding Largest Customer Up 52%; Operating Loss and Cash Use

Artificial Intelligence Technology Solutions Inc. (AITX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Artificial Intelligence Technology Solutions, Inc.: Exhibit 99.1 - Filed by newsfilecorp.com Exhibit 99.1 AITX Confirms Audited Fiscal Year 2026 Results and Files Form 10-K, Reinforcing Revenue Growth, Gross Margin Expansion, and Its Three-

BioNTech (BNTX) stock fell 8.3% after terminating a Phase 2 cancer trial due to survival imbalance. The setback follows recent optimism in the neoantigen vaccine space and raises concerns about its oncology pipeline. The FDA's anticipated COVID-19 vaccine approval did not offset investor worries.

Microsoft's Xbox division is reportedly seeking a $300M deal to sell film and TV rights to over a dozen game franchises, including Halo, Warcraft, and The Elder Scrolls. Studios like Netflix, Paramount, and Universal are evaluating the offer, which follows Microsoft's 2023 acquisition of Activision Blizzard. Past adaptations had mixed success, but recent hits like Amazon's Fallout series have shown potential. The deal could provide financial stability amid gaming sector volatility and recent lay

BioNTech SE (BNTX) shares fell 10% after terminating a Phase 2 mRNA cancer vaccine trial for colorectal cancer due to futility. The setback contrasts with Moderna's recent success in melanoma, highlighting different outcomes in cancer types. BioNTech has €16.6B in cash and securities, and other trials remain ongoing. Investors await further data at ESMO Congress in October 2026.

AstraZeneca's Phase III trial for ATTR-CM treatment showed no benefit over stabilizers. STAT News reports. The drug is part of the multibillion-dollar heart disease market. Separately, a US appeals court upheld the FDA's decision to end shortages of Novo Nordisk and Eli Lilly diabetes/obesity drugs, limiting compounded-drug manufacturers' production.